Literature DB >> 16150790

Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography.

N J Peake1, H E Foster, K Khawaja, T E Cawston, A D Rowan.   

Abstract

OBJECTIVE: To measure gelatinase activities in paired synovial fluid (SF) and serum of patients with juvenile idiopathic arthritis (JIA), and to assess how these activities relate to clinical and laboratory measures of disease activity.
METHODS: A quantitative protein substrate zymography method was adapted and validated for use with serum and SF. Bands of activity were measured by densitometry and correlated with standard laboratory indicators of inflammation: erythrocyte sedimentation rate and platelet count.
RESULTS: Gelatinase activity was found consistently in patients with JIA, with reproducible, quantified bands of activity corresponding to pro-matrix metalloproteinase-9 (pro-MMP-9), including the neutrophil associated lipocalin complex, and pro- and active forms of MMP-2. Both active MMP-2 and pro-MMP-9 were higher in JIA serum than in controls, though no differences were seen between patients grouped according to age, disease duration, or JIA subtype. However, SF MMP-9 correlated significantly with the laboratory indicators of inflammation, as did the relative level of active MMP-2.
CONCLUSIONS: Both MMP-2 and MMP-9 gelatinolytic activities are raised during active JIA and associated with inflammatory activity regardless of age and disease duration, supporting a role for MMPs in the breakdown of joint components from early in disease. These MMPs may be specific markers of active joint destruction linked to inflammatory JIA, MMP-9 as a product of infiltrating cells, and the activation of MMP-2 produced within the joint.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150790      PMCID: PMC1798108          DOI: 10.1136/ard.2005.039032

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  34 in total

1.  Biomechanical regulation of matrix metalloproteinase-9 in cultured chondrocytes.

Authors:  G Jin; R L Sah; Y S Li; M Lotz; J Y Shyy; S Chien
Journal:  J Orthop Res       Date:  2000-11       Impact factor: 3.494

2.  Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1.

Authors:  M W Olson; M M Bernardo; M Pietila; D C Gervasi; M Toth; L P Kotra; I Massova; S Mobashery; R Fridman
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

3.  Chondrocyte cultures express matrix metalloproteinase mRNA and immunoreactive protein; stromelysin-1 and 72 kDa gelatinase are localized in extracellular matrix vesicles.

Authors:  J P Schmitz; D D Dean; Z Schwartz; D L Cochran; G M Grant; R J Klebe; H Nakaya; B D Boyan
Journal:  J Cell Biochem       Date:  1996-06-01       Impact factor: 4.429

4.  Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation.

Authors:  E B Springman; E L Angleton; H Birkedal-Hansen; H E Van Wart
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

5.  The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis.

Authors:  K A Hasty; R A Reife; A H Kang; J M Stuart
Journal:  Arthritis Rheum       Date:  1990-03

6.  Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines.

Authors:  E N Unemori; M S Hibbs; E P Amento
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

7.  Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments.

Authors:  R T Aimes; J P Quigley
Journal:  J Biol Chem       Date:  1995-03-17       Impact factor: 5.157

8.  Matrix metalloproteinases 2 and 9 in canine rheumatoid arthritis.

Authors:  A R Coughlan; D H Robertson; D Bennett; C May; R J Beynon; S D Carter
Journal:  Vet Rec       Date:  1998-08-22       Impact factor: 2.695

9.  Direct activation of human neutrophil procollagenase by recombinant stromelysin.

Authors:  V Knäuper; S M Wilhelm; P K Seperack; Y A DeClerck; K E Langley; A Osthues; H Tschesche
Journal:  Biochem J       Date:  1993-10-15       Impact factor: 3.857

10.  Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage.

Authors:  J Dudhia; C M Davidson; T M Wells; D H Vynios; T E Hardingham; M T Bayliss
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

View more
  13 in total

1.  Expression of matrix metalloproteinases 2 and 9 in human gastric cancer and superficial gastritis.

Authors:  Clara Luz Sampieri; Sol de la Peña; Mariana Ochoa-Lara; Roberto Zenteno-Cuevas; Kenneth León-Córdoba
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

2.  Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-alpha-308GG genotype.

Authors:  Jelena Basic; Dusica Pavlovic; Tatjana Jevtovic-Stoimenov; Jelena Vojinovic; Gordana Susic; Ivana Stojanovic; Gordana Kocic; Vuk Milosevic; Tatjana Cvetkovic; Milena Marinkovic; Andrej Veljkovic
Journal:  J Physiol Biochem       Date:  2010-07-02       Impact factor: 4.158

3.  Multiple matrix metalloproteinases in type II collagen induced arthritis.

Authors:  S Sandya; M A Achan; P R Sudhakaran
Journal:  Indian J Clin Biochem       Date:  2009-05-08

4.  Salivary antioxidants and metalloproteinases in juvenile idiopathic arthritis.

Authors:  Riva Brik; Irit Rosen; Dana Savulescu; Iris Borovoi; Moshe Gavish; Rafael Nagler
Journal:  Mol Med       Date:  2009-12-28       Impact factor: 6.354

5.  Role of osteopontin in neutrophil function.

Authors:  Adeline Koh; Andre Paes Batista da Silva; Anil K Bansal; Manju Bansal; Chunxiang Sun; Hyejin Lee; Michael Glogauer; Jaro Sodek; Ron Zohar
Journal:  Immunology       Date:  2007-08-03       Impact factor: 7.397

6.  Concerted Actions by PIICP, CTXII, and TNF-α in Patients with Juvenile Idiopathic Arthritis.

Authors:  Katarzyna Winsz-Szczotka; Kornelia Kuźnik-Trocha; Iwona Lachór-Motyka; Wojciech Lemski; Krystyna Olczyk
Journal:  Biomolecules       Date:  2021-04-28

7.  Secondary osteoporosis in patients with juvenile idiopathic arthritis.

Authors:  Kristyna Brabnikova Maresova
Journal:  J Osteoporos       Date:  2011-02-20

8.  MMP-2 Isoforms in Aortic Tissue and Serum of Patients with Ascending Aortic Aneurysms and Aortic Root Aneurysms.

Authors:  Anke Tscheuschler; Philipp Meffert; Friedhelm Beyersdorf; Claudia Heilmann; Nadja Kocher; Xenia Uffelmann; Philipp Discher; Matthias Siepe; Fabian A Kari
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

9.  A cross-sectional cohort study of the activity and turnover of neutrophil granulocytes in juvenile idiopathic arthritis.

Authors:  Malin Backlund; Per Venge; Lillemor Berntson
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-30       Impact factor: 3.054

10.  Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug.

Authors:  Grant R Zimmermann; William Avery; Alyce L Finelli; Melissa Farwell; Christopher C Fraser; Alexis A Borisy
Journal:  Arthritis Res Ther       Date:  2009-01-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.